Evaluation of circulating tumor DNA as a biomarker for ...

The detection and analysis of ctDNA can provide genomic information on the size and development of tumor; therefore, it is considered as an emerging and ...

Evaluation of circulating tumor DNA as a prognostic biomarker for ...

The ctDNA has the potential as a specific survival predictive marker for metastatic PAC patients. Longitudinal ctDNA tracking could ...

Evaluation of circulating tumor DNA as a prognostic biomarker for ...

The present study evaluated circulating tumor DNA (ctDNA) as a biomarker for prognosis prediction and disease monitoring in metastatic pancreatic ...

Early evaluation of circulating tumor DNA as marker of therapeutic ...

ctDNA was found to be detected in 51.4% (37/72) of patients before the start of PST in our study. However, baseline ctDNA positivity rate varies significantly ...

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic ...

Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.

Evaluation of circulating tumor DNA as a biomarker in pancreatic ...

This study supports the use of circulating tumor DNA as an independent prognostic marker for advanced pancreatic cancer.

Circulating Tumor DNA as a Biomarker for Monitoring Patients with ...

For most patients with cancer, ctDNA forms a low proportion of the total circulating free DNA (cfDNA), i.e., frequently <1% (4). However, since ...

Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal ...

Evaluation of circulating tumor DNA as a liquid biomarker in uveal melanoma. Daniel P. de Bruyn; Natasha M. van Poppelen; Tom Brands; Susanne C. van den Boom.

Longitudinal on-treatment circulating tumor DNA as a biomarker for ...

Recurrence risks of cancer patient can change during treatment as a result of treatment-related tumor evolution. However, biomarkers that can monitor these ...

Analytical evaluation of circulating tumor DNA sequencing assays

In China, circulating tumor DNA analysis is widely used and numerous assays are available. Systematic evaluation to help users make informed ...

Longitudinal evaluation of circulating tumor DNA (ctDNA) as a ...

Longitudinal evaluation of circulating tumor DNA (ctDNA) as a prognostic biomarker to detect minimal residual disease (MRD) in testicular cancer ...

Recent Advancements in the Application of Circulating Tumor DNA ...

Tumor cell DNA circulating in the blood, commonly referred to as circulating tumor DNA, or ctDNA, is one kind of biomarker that has attracted ...

Circulating tumor DNA: a promising biomarker in the liquid biopsy of ...

found similar results [85]. Therefore, ctDNA has potential to be used for the evaluation of tumor progression and prognostic. In summary, liquid ...

Plasma ctDNA as a Treatment Response Biomarker in Metastatic ...

In people with cancer, a fraction of circulating cell-free DNA (cfDNA) in blood plasma is tumor-derived and is known as ctDNA (refs. 9, 10).

Circulating Tumor DNA as a Cancer Biomarker - Frontiers

found out increased levels of cfDNA in the serum of cancer patients (9), highlighting its huge potential as a tumor biomarker. cfDNA is generally at a ...

Circulating tumor DNA as prognostic markers of relapsed breast ...

The ctDNA can be used as an early potential postoperative prognosis biomarker in breast cancer, and also as a reference index to evaluate the therapeutic ...

Regulatory implications of ctDNA in immuno-oncology for solid tumors

Circulating tumor DNA (ctDNA) is an increasingly important biomarker being developed for the diagnosis and management of patients with cancer ...

Molecular response assessment using circulating tumor DNA ...

The most common readout for a mutation detected in ctDNA is the variant allele frequency (VAF), defined as the fraction of cfDNA molecules ...

Using Circulating Tumor DNA in Colorectal Cancer: Current and ...

The clearance of ctDNA is also a potential biomarker that could help with early assessment of therapeutic efficacy. ctDNA testing also generally ...

Prospective Evaluation of Circulating Tumor DNA using Next...

Circulating tumor DNA is a promising blood-based biomarker that is prognostic in several malignancies. Detection of ctDNA by NGS may provide ...